These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21607331)

  • 41. Cardiotoxicity of the antiproliferative compound fluorouracil.
    Becker K; Erckenbrecht JF; Häussinger D; Frieling T
    Drugs; 1999 Apr; 57(4):475-84. PubMed ID: 10235688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies of hematopoietic stem cells spared by 5-fluorouracil.
    Van Zant G
    J Exp Med; 1984 Mar; 159(3):679-90. PubMed ID: 6699542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential toxicity and pharmacokinetics of sodium and Tris salts of 5-fluorouracil in the rat.
    Plumb JA; Gardner ML
    Clin Sci (Lond); 1981 Jun; 60(6):707-10. PubMed ID: 7249549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro cytotoxicity and in vivo efficacy of 5-fluorouracil-loaded enteric-coated PEG-cross-linked chitosan microspheres in colorectal cancer therapy in rats.
    Ganguly K; Kulkarni AR; Aminabhavi TM
    Drug Deliv; 2016 Oct; 23(8):2838-2851. PubMed ID: 26530807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice.
    Yu NY; Orenberg EK; Luck EE; Brown DM
    Cancer Chemother Pharmacol; 1995; 36(1):27-34. PubMed ID: 7720172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy of single-dose 5-fluorouracil therapy in experimental caustic esophageal burn.
    Duman L; Büyükyavuz BI; Altuntas I; Gökcimen A; Ceyhan L; Darici H; Aylak F; Tomruk O
    J Pediatr Surg; 2011 Oct; 46(10):1893-7. PubMed ID: 22008323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
    Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
    Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wound modulation after trabeculectomy by different formulations of antimetabolites in rabbits.
    Lu DW; Chang CJ; Chiang CH; Yeh MK; Chou PI
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):529-38. PubMed ID: 11132900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regional injection of 5-fluorouracil and starch microspheres in colorectal cancer.
    Ball AS; Mann CV; Clifton MA; Baker WN; Goode AW
    Acta Chir Scand; 1988 Sep; 154(9):521-4. PubMed ID: 3201864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.
    Fanciullino R; Giacometti S; Aubert C; Fina F; Martin PM; Piccerelle P; Ciccolini J
    Pharm Res; 2005 Dec; 22(12):2051-7. PubMed ID: 16222443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
    Bading JR; Alauddin MM; Fissekis JD; Shahinian AH; Joung J; Spector T; Conti PS
    J Nucl Med; 2000 Oct; 41(10):1714-24. PubMed ID: 11038003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
    Fanciullino R; Giacometti S; Mercier C; Aubert C; Blanquicett C; Piccerelle P; Ciccolini J
    Br J Cancer; 2007 Oct; 97(7):919-26. PubMed ID: 17848948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
    Kissel J; Brix G; Bellemann ME; Strauss LG; Dimitrakopoulou-Strauss A; Port R; Haberkorn U; Lorenz WJ
    Cancer Res; 1997 Aug; 57(16):3415-23. PubMed ID: 9270007
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Stability of 5-fluorouracil solutions according to different parameters].
    Barberi-Heyob M; Watelet M; Merlin JL; Bleger C; Schroeder B
    Bull Cancer; 1995 Dec; 82(12):1025-31. PubMed ID: 8745668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
    Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
    Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine.
    Eskandari MR; Moghaddam F; Shahraki J; Pourahmad J
    Xenobiotica; 2015 Jan; 45(1):79-87. PubMed ID: 25034007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Acute cardiac toxicity of 5-fluorouracil: pharmacokinetic correlation].
    Gamelin E; Gamelin L; Larra F; Turcant A; Alain P; Maillart P; Allain YM; Minier JF; Dubin J
    Bull Cancer; 1991; 78(12):1147-53. PubMed ID: 1786427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
    Nakayama Y; Matsumoto K; Inoue Y; Katsuki T; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
    Anticancer Res; 2006; 26(5B):3983-8. PubMed ID: 17094430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
    Maurer U; Härle M; Jungius KP
    Strahlenther Onkol; 1996 May; 172(5):257-9. PubMed ID: 8633257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.